|
ATE428421T1
(de)
*
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
CN101316590B
(zh)
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
|
WO2007136103A1
(ja)
*
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
|
EP2119707B1
(en)
*
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
CN101848895B
(zh)
*
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
BR112012003592B8
(pt)
|
2009-08-19 |
2021-05-25 |
Eisai R&D Man Co Ltd |
composição farmacêutica contendo derivado de quinolina
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
WO2012122444A1
(en)
|
2011-03-10 |
2012-09-13 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
|
EP2700403B1
(en)
*
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
AU2013263076B2
(en)
|
2012-05-15 |
2017-08-31 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
FI3381942T4
(fi)
*
|
2012-08-30 |
2025-12-16 |
Amgen Inc |
Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
TW201427681A
(zh)
*
|
2013-01-07 |
2014-07-16 |
Superlab Far East Ltd |
用空間構象改變的重組干擾素治療腫瘤的方法
|
|
US12421502B2
(en)
|
2013-04-18 |
2025-09-23 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
DK3461491T3
(da)
|
2013-04-18 |
2025-02-03 |
Tilt Biotherapeutics Oy |
Forbedret adoptiv celleterapi
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
EP3834838A1
(en)
*
|
2014-02-21 |
2021-06-16 |
Nektar Therapeutics (India) Pvt. Ltd. |
Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
|
|
WO2015127407A1
(en)
*
|
2014-02-21 |
2015-08-27 |
Stemcentrx, Inc. |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
RU2695332C2
(ru)
|
2014-05-15 |
2019-07-23 |
Бристол-Маерс Сквибб Компани |
Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
|
|
CA2957005C
(en)
|
2014-08-28 |
2021-10-12 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
CA2971216A1
(en)
|
2014-12-23 |
2016-06-30 |
The Regents Of The University Of California |
Methods for immunomodulation of cancer and infectious disease therapy
|
|
CN104459129A
(zh)
*
|
2015-01-05 |
2015-03-25 |
复旦大学附属华山医院 |
一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
|
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
SI3858859T1
(sl)
|
2015-07-14 |
2026-03-31 |
Bristol-Myers Squibb Company |
Postopek zdravljenja raka z uporabo zaviralca imunskih kontrolnih točk; protitelo, ki se veže na receptor programirane celične smrti-1 (pd-1) ali ligand programirane celične smrti 1 (pd-l1)
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
RU2719486C2
(ru)
|
2015-11-11 |
2020-04-17 |
Агалиммьюн Лимитед |
Гликолипидные соединения и их применение в лечении опухолей
|
|
CN108350081A
(zh)
|
2015-11-18 |
2018-07-31 |
百时美施贵宝公司 |
使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
|
|
US10130658B2
(en)
*
|
2015-12-18 |
2018-11-20 |
Provectus Pharmatech, Inc. |
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
|
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
US20190111111A1
(en)
*
|
2016-04-13 |
2019-04-18 |
The Regents Of The University Of California |
Treatment of Cerebral Cavernous Malformations
|
|
EP3458092A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
WO2017201325A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
|
DK3458083T5
(da)
|
2016-05-18 |
2024-10-21 |
Modernatx Inc |
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
|
|
IL292302B2
(en)
|
2016-05-20 |
2023-10-01 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating factors in cancer immunotherapy
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CN109475633A
(zh)
|
2016-06-02 |
2019-03-15 |
百时美施贵宝公司 |
在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
|
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
|
KR102702675B1
(ko)
|
2016-06-03 |
2024-09-05 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
|
US20190315865A1
(en)
|
2016-10-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
|
CN110291089B
(zh)
|
2017-01-17 |
2022-05-27 |
海帕瑞吉尼克斯股份有限公司 |
用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MX2019012741A
(es)
|
2017-04-28 |
2020-01-21 |
Merck Sharp & Dohme |
Biomarcadores para agentes terapeuticos contra el cancer.
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
US11421011B2
(en)
|
2017-05-18 |
2022-08-23 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
|
MX2019012038A
(es)
|
2017-05-30 |
2019-11-18 |
Bristol Myers Squibb Co |
Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
|
|
GB201710097D0
(en)
*
|
2017-06-23 |
2017-08-09 |
Univ Ulster |
A sensitizer - peptide conjugate
|
|
JP7341130B2
(ja)
|
2017-09-29 |
2023-09-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
癌を治療するための組成物および治療方法
|
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019075468A1
(en)
|
2017-10-15 |
2019-04-18 |
Bristol-Myers Squibb Company |
TUMOR TREATMENT METHODS
|
|
EP3700520B1
(en)
|
2017-11-29 |
2024-05-01 |
The Rockefeller University |
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
|
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
US20190224205A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3773548B1
(en)
*
|
2018-05-16 |
2023-08-09 |
Provectus Pharmatech, Inc. |
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
|
|
BR112020023955A2
(pt)
|
2018-05-27 |
2021-02-23 |
Biolinerx Ltd. |
agi-134 combinado com um inibidor de ponto de controle para o tratamento de tumores sólidos
|
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
KR20210081384A
(ko)
|
2018-10-23 |
2021-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
BR112021009111A2
(pt)
|
2018-11-16 |
2021-08-24 |
Bristol-Myers Squibb Company |
Anticorpos anti-nkg2a e usos dos mesmos
|
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
|
US20220016079A1
(en)
|
2018-11-26 |
2022-01-20 |
Debiopharm International S.A. |
Combination treatment of hiv infections
|
|
GB201819853D0
(en)
*
|
2018-12-05 |
2019-01-23 |
Innovation Ulster Ltd |
Therapy
|
|
CN113453712A
(zh)
|
2018-12-28 |
2021-09-28 |
特兰斯吉恩股份有限公司 |
M2缺陷型痘病毒
|
|
US20220195046A1
(en)
|
2019-03-28 |
2022-06-23 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2020198672A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
CN114450028A
(zh)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Lag-3拮抗剂治疗的定量空间剖析
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
AU2019474803B2
(en)
*
|
2019-11-19 |
2024-11-07 |
Provectus Pharmatech, Inc. |
Composition and method for treating hematologic cancers
|
|
US11419844B2
(en)
|
2019-11-19 |
2022-08-23 |
Provectus Pharmatech, Inc. |
Halogenated xanthene composition and method for treating hematologic cancers
|
|
US12064507B2
(en)
|
2019-11-19 |
2024-08-20 |
Provectus Pharmatech, Inc. |
Composition and method for oral treatment of leukemia
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
KR20220139915A
(ko)
|
2020-02-06 |
2022-10-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-10 및 그의 용도
|
|
US11938182B2
(en)
|
2020-03-26 |
2024-03-26 |
Provectus Pharmatech, Inc. |
Halogenated xanthenes as vaccine adjuvants
|
|
EP4103283A4
(en)
*
|
2020-03-26 |
2024-02-28 |
Provectus Pharmatech, Inc. |
NEW USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY
|
|
WO2021243207A1
(en)
|
2020-05-28 |
2021-12-02 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
CA3193421A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
CA3190660A1
(en)
|
2020-08-31 |
2022-03-03 |
George C. Lee |
Cell localization signature and immunotherapy
|
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
SMT202500208T1
(it)
|
2020-12-28 |
2025-07-22 |
Bristol Myers Squibb Co |
Composizioni anticorpali e metodi per il loro uso
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
US20240417473A1
(en)
|
2021-10-29 |
2024-12-19 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
IL314050A
(en)
|
2022-01-26 |
2024-09-01 |
Bristol Myers Squibb Co |
Combination therapy for hepatocellular carcinoma
|
|
EP4482947A1
(en)
|
2022-02-24 |
2025-01-01 |
Amazentis SA |
Uses of urolithins
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
JP2025508076A
(ja)
|
2022-03-08 |
2025-03-21 |
アレンティス・セラピューティクス・アクチェンゲゼルシャフト |
Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
US20260042840A1
(en)
|
2022-04-07 |
2026-02-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
CN119562830A
(zh)
|
2022-06-02 |
2025-03-04 |
百时美施贵宝公司 |
抗体组合物及其使用方法
|
|
AU2023300419A1
(en)
|
2022-07-01 |
2025-01-02 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
US20260048049A1
(en)
|
2022-08-18 |
2026-02-19 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
CN120731228A
(zh)
|
2022-12-21 |
2025-09-30 |
百时美施贵宝公司 |
肺癌的组合疗法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025184211A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
US20260115307A1
(en)
|
2024-10-31 |
2026-04-30 |
Bristol-Myers Squibb Company |
Anti-fucosyl-gm1 antibody drug conjugates
|